Adelene Perkins

CEO

Adelene Perkins has served as Infinity’s CEO and Chair since 2012, CEO and Board Member since 2009, President from 2008-2009 and EVP and CBO from 2002-2008. Previously, Ms. Perkins served as TransForm Pharmaceuticals’ VP of BD and helped build the company prior to its acquisition by J&J. From 1992-1999 she was at Genetics Institute (GI), now a unit of Pfizer, as VP of emerging businesses and formed and served as CEO of MetaMorphix, a joint venture between GI and Johns Hopkins University. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm. Ms. Perkins received her MBA from Harvard Business School and her BS in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is vice chairman of the Board of Project Hope.